Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Clinical trial NCT03773302 · TERMINATED

Trial details

NCT number: NCT03773302
Sponsor: QED Therapeutics, a BridgeBio company
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Cholangiocarcinoma FGFR2 Gene Mutation

Start date: 2019-12-27
Primary completion: 2023-03-02
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.